Provention bio cancels fourth quarter and full year 2022 earnings release and conference call

Red bank, n.j. , march 13, 2023 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended december 31, 2022 due to the announcement earlier today that provention has entered into a definitive agreement to be acquired by sanofi, provention's u.s. tzield co-promotion partner, subject to customary regulatory and other closing conditions.
PRVB Ratings Summary
PRVB Quant Ranking